Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7624 add-on therapy for frequent exacerbations in COPD
NL-OMON41136Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD7624 add-on with Placebo add-on (2 arms). Primary endpoint: Time to first composite exacerbation or worsening-related early dropout. Started Oct 2014; status: active, not recruiting.
02
Drugs
AZD7624
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON41136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41136.